APA (7th ed.) Citation

Cortes, J. E., Roboz, G. J., Baer, M. R., Jonas, B. A., Schiller, G. J., Yee, K., . . . Watts, J. M. (2025). Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: A multicohort open-label phase 1/2 trial. Journal of Hematology & Oncology, 18(1), 1. https://doi.org/10.1186/s13045-024-01657-z

Chicago Style (17th ed.) Citation

Cortes, Jorge E., et al. "Olutasidenib in Combination with Azacitidine Induces Durable Complete Remissions in Patients with Relapsed or Refractory MIDH1 Acute Myeloid Leukemia: A Multicohort Open-label Phase 1/2 Trial." Journal of Hematology & Oncology 18, no. 1 (2025): 1. https://doi.org/10.1186/s13045-024-01657-z.

MLA (9th ed.) Citation

Cortes, Jorge E., et al. "Olutasidenib in Combination with Azacitidine Induces Durable Complete Remissions in Patients with Relapsed or Refractory MIDH1 Acute Myeloid Leukemia: A Multicohort Open-label Phase 1/2 Trial." Journal of Hematology & Oncology, vol. 18, no. 1, 2025, p. 1, https://doi.org/10.1186/s13045-024-01657-z.